Azalanstat

Drug Profile

Azalanstat

Alternative Names: RS 21607; RS 21607-007; RS 21607-197

Latest Information Update: 14 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antihyperlipidaemics
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 01 Jun 1999 No-Development-Reported for Hyperlipidaemia in Switzerland (PO)
  • 01 Jun 1999 No-Development-Reported for Hyperlipidaemia in USA (PO)
  • 08 Nov 1995 Animal studies have been added to the pharmacodynamics section for Antihyperlipidaemics .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top